Artia Global Partners LP Acquires 309,098 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Artia Global Partners LP lifted its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 158.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 503,936 shares of the company’s stock after purchasing an additional 309,098 shares during the period. NewAmsterdam Pharma comprises about 2.4% of Artia Global Partners LP’s investment portfolio, making the stock its 11th biggest position. Artia Global Partners LP owned 0.44% of NewAmsterdam Pharma worth $17,678,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in NAMS. Capital World Investors grew its holdings in shares of NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after purchasing an additional 1,434,986 shares during the last quarter. Duquesne Family Office LLC grew its holdings in shares of NewAmsterdam Pharma by 131.2% during the 3rd quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after purchasing an additional 1,091,525 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after purchasing an additional 1,062,359 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of NewAmsterdam Pharma by 96.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock valued at $60,536,000 after purchasing an additional 845,110 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of NewAmsterdam Pharma by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after purchasing an additional 697,129 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $30.15 on Thursday. The stock has a market capitalization of $3.52 billion, a PE ratio of -16.84 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 52-week low of $17.63 and a 52-week high of $42.21. The company has a 50-day simple moving average of $33.26 and a two-hundred day simple moving average of $33.42.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The firm had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. As a group, equities research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on NAMS. Guggenheim increased their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Finally, HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.60.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total value of $2,319,850.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $869,158.57. The trade was a 72.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.